tbuckley/cabot-search huggingface dataset:
Septal Reduction Strategies in Hypertrophic Cardiomyopathy—The Scalpel, Catheter, or Wire?
Authors: Dana Roxana Bataiosu, Harry Rakowski
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
LEAVE NO STONE UNTURNED - COMPLETE REVASCULARIZATION OF SVG TO OM IN-STENT RESTENOSIS AND LM TO LAD CTO (IN-STENT RESTENOSIS) IN A TAKAYASU’S PATEINT WITH A HISTORY OF COROANRY INVOLVEMENT AND REDO CABG.
Authors: Isaac Tea, Syed Zaid, Tomoya Timothy Hinohara, Neal S. Kleiman, Alpesh R. Shah
Journal: Journal of the American College of Cardiology (2022)
Abstract P3-14-04: Genetic testing in non-Hispanic Black women with breast cancer treated within an equal-access healthcare system
Authors: Rachel Ellsworth, Ashlee Vargason, Clesson Turner, Craig Shriver
Journal: Cancer Research (2022)

Abstract Purpose: Identification of women with hereditary forms of cancer allows for use of precision medicine approaches to improve survival. Non-Hispanic Black (NHB) women in the US general population are less likely to undergo genetic testing or utilize risk-reducing strategies. Whether these disparities exist within the equal-access military healthcare system of the Department of Defense is not known. Methods: Genetic test information and surgical procedures were extracted for all NHB and Non-Hispanic Whites (NHW) with invasive breast cancer who were diagnosed and treated at the Murtha Cancer Center at Walter Reed National Military Medical Center and enrolled in the Clinical Breast Care Project. National Comprehensive Cancer Network criteria from the year of diagnosis were assessed for all patients. Data were analyzed using chi-square analysis with p&amp;lt;0.05 defining significance. Results: NHB were significantly (p=0.009) more likely to meet criteria for genetic testing compared to NHW, however, test uptake did not differ significantly between populations (p=0.292). Pathogenic variant frequency (p=0.597), prophylactic mastectomy (p=0.915) and oophorectomy (p=0.076) did not differ significantly between populations. Conclusion: These data demonstrate that when barriers, such as cost and lack of insurance barriers were removed, NHB were as willing to pursue testing and risk-reducing strategies as their NHW counterparts. Increasing the availability of testing and clinical management for NHB with hereditary forms of cancer may help reduce disparate survival seen in the US general population. The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions or policies of Uniformed Services University of the Health Sciences (USUHS), The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense (DoD) or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. Citation Format: Rachel Ellsworth, Ashlee Vargason, Clesson Turner, Craig Shriver. Genetic testing in non-Hispanic Black women with breast cancer treated within an equal-access healthcare system [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-14-04.
OUTCOMES OF LONG TERM AMIODARONE USE FOR VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES
Authors: John Larson, Amrish Deshmukh, Andrew Chou, Keerthi Gondi, Michael Ghannam, Thomas Cascino, Rakesh Latchamsetty, Keith D. Aaronson, Hakan Oral, Fred Morady, Francis D. Pagani, Frank M. Bogun, Jackson J. Liang
Journal: Journal of the American College of Cardiology (2022)
Abstract P5-09-04: Regulation of mTOR signaling pathway by ING4 in breast cancer: A new target in cancer therapy
Authors: Aymen Shatnawi, Travis Salisbury
Journal: Cancer Research (2022)

Abstract Background: Breast cancer (BC) is one of the most diagnosed tumors in the United States. The mechanism of the disease development and progression is complex and still not fully understood. Dysregulation or change in the expression of transcription factors has been proposed as a possible cause of the disease severity and poor prognosis. The INhibitor of Growth family member 4 (ING4) is a tumor suppressor that has been connected to various cancer-related processes. Therefore, this study aims to assess the global gene regulation of BC cells by ING4 and identify the associated cellular processes and molecular pathways related to BC following ING4 loss. Methods: siRNA Knockdown and CRISPR Knockout technologies were used to deplete ING4 expression. Real-time PCR, RNA-Seq and Chip-Seq were used to identify gene expression alteration and ING4 enrichment on target promoters. Ingenuity Pathways Analysis (IPA®) was used to highlight candidates, networks and cellular processes. Results: Protein and RNA levels of ING4 were significantly reduced in MDA-231 knockdown and MCF7 knockout cells using siRNA and CRISPR technologies. RNA-Seq of BC cells revealed a large set of differentially expressed genes were regulated following ING4 loss. Key genes and biological networks related to cellular processes, including amino acid metabolism, cancer, cellular development, cellular growth and proliferation, were identified using IPA®. Chip-seq also revealed that ING4 was recruited to genes important in BC development and progression. Several genes were validated using the RT-qPCR method, and results were consistent with RNA-seq and Chip-seq data. Importantly, MDA-231 cells grown in stripped serum have shown an upregulation of the ribosomal protein S6 phosphorylation (PS6), an mTOR target protein, following ING4 knockdown. Treatment of MDA-231 cells with rapamycin blocked the phosphorylation of S6 induced by ING4 loss. An increase in S6 phosphorylation was also observed in MCF7 knockout cells grown either in regular or serum-free growth medium. The phosphorylation was reversed by amino acid transporter inhibitors JPH and BCH. Conclusion: The present study shows that ING4 regulates many genes involved in biological pathways and networks related to BC development and progression. Importantly, ING4 is a novel regulator of the mTOR pathway. Collectively, regulation of ING4 gene expression and its downstream molecules provides a novel approach in cancer treatment. Citation Format: Aymen Shatnawi, Travis Salisbury. Regulation of mTOR signaling pathway by ING4 in breast cancer: A new target in cancer therapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-09-04.
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Authors: Lupeng Ye, Jonathan J Park, Lei Peng, Quanjun Yang, Ryan D Chow, Matthew B Dong, Stanley Z Lam, Jianjian Guo, Erting Tang, Yueqi Zhang, Guangchuan Wang, Xiaoyun Dai, Yaying Du, Hyunu R Kim, Hanbing Cao, Youssef Errami, Paul Clark, Alexey Bersenev, Ruth R Montgomery, Sidi Chen
Journal: Cell Metabolism (2022)
Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning
Authors: Mijin Kim, Chen Chen, Peng Wang, Joseph J. Mulvey, Yoona Yang, Christopher Wun, Merav Antman-Passig, Hong-Bin Luo, Sun Cho, Kara Long-Roche, Lakshmi V. Ramanathan, Anand Jagota, Ming Zheng, YuHuang Wang, Daniel A. Heller
Journal: Nature Biomedical Engineering (2022)
Risk of Colorectal Cancer Associated With Lifetime Excess Weight
Authors: Xiangwei Li, Lina Jansen, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner
Journal: JAMA Oncology (2022)

Excess weight is associated with increased cancer risk, but the risk may have been underestimated, as previous studies did not consider cumulative lifetime exposure.To assess the association of cumulative lifetime excess weight with risk of colorectal cancer (CRC).In a population-based case-control study conducted since 2003 in Germany, height and self-reported weight documented in 10-year increments starting at age 20 years up to the current age were obtained from 5635 individuals with CRC and 4515 persons serving as controls. Body mass index (BMI), calculated as weight in kilograms divided by height in meters squared, was calculated for each year of age from age 20 years to the current age by linear interpolation. Excess BMI (eBMI) at each year of age was determined as BMI - 25 and summed across ages to obtain the weighted number of years lived with overweight or obesity (WYOs), determined as year × eBMI. The eBMI was set to 0 in case of a BMI below 25. Associations with CRC risk were estimated for BMI at various ages and for WYOs by multiple logistic regression. Data analyses were performed from June 4, 2021, to December 17, 2021.Relative risk of CRC according to lifetime exposure to excess weight compared with relative risks according to BMI at various ages.The mean (SD) age of the patients with CRC (n = 5635) was 68.4 (10.9) years; 3366 were men (59.7%); mean (SD) age of the control participants (n = 4515) was 68.5 (10.6) years; 2759 were men (61.1%). An association was observed between WYOs and CRC risk, with adjusted odds ratios (ORs) increasing from 1.25 (95% CI, 1.09-1.44) to 2.54 (95% CI, 2.24-2.89) from the first to the fourth quartile of WYOs compared with participants who remained within the normal weight range. Each SD increment in WYOs was associated with an increase of CRC risk by 55% (adjusted OR, 1.55; 95% CI, 1.46-1.64). This OR was higher than the OR per SD increase of eBMI at any single point of time, which ranged from 1.04 (95% CI, 0.93-1.16) to 1.27 (95% CI 1.16-1.39).The results of this case-control study suggest a greater role of cumulative lifetime excess weight for CRC risk than estimated by traditional analyses based on BMI measures taken at a single point.
Financial Toxicity of Cancer Treatment
Authors: S. M. Qasim Hussaini, Arjun Gupta, Stacie B. Dusetzina
Journal: JAMA Oncology (2022)

What Is Financial Toxicity?Cancer is one of the most expensive medical conditions to treat in the US.Financial toxicity is a term used to describe the harmful effect of high cost of treatment on a person's quality of life.It may also be described as financial burden or financial distress.Am I at Risk of Financial Toxicity During Treatment?Many factors may cause financial stress during treatment: • Type of cancer, its severity, and treatment: Treatment may range from a single daily pill to daily or weekly visits or long hospital stays.• Financial status: Factors include whether you are the primary earner in your family, how much money you have saved, and whether you or a family member can continue working during treatment.• Health insurance coverage: This dictates your out-of-pocket costs during treatment.What Are the Consequences of Financial Distress During Treatment?
PROGNOSTIC VALUE AND PREDICTORS OF DECREASED SKELETAL MUSCLE MASS ON CARDIAC MAGNETIC RESONANCE IMAGING IN PATIENTS UNDERGOING AORTIC VALVE SURGERY
Authors: Saeid Mirzai, Meghana A. Patil, Felix O. Berglund, Pooja Podugu, Hussein Awwad, Tom Kai Ming Wang, Po-Hao Chen, Lars G. Svensson, W.H. Wilson Tang, Deborah Kwon
Journal: Journal of the American College of Cardiology (2022)
TWO DECADE TRENDS IN CARDIOVASCULAR DISEASE RISK FACTOR AND OUTCOME BURDEN AMONG VETERANS WITH HIV
Authors: Mohammed S. Haji, Augustus Ge, Christopher Halladay, Cullen Soares, Nishant R. Shah, David Ross, Jennifer L. Sullivan, James L. Rudolph, Wen-Chih Wu, Sebhat Erqou
Journal: Journal of the American College of Cardiology (2022)
ACUTE ST ELEVATION MYOCARDIAL INFARCTION (MI) IN YOUNG HEALTHY PATIENT FOLLOWING (MRNA) COVID-19 VACCINE
Authors: Mohammad Altermanini, Mhd Baraa Habib, Tarek Aboursheid, Mohamad Hijazi, Bassel Bitar, Ashraf Omer Ahmed, Mohamed Salah Abdelghani
Journal: Journal of the American College of Cardiology (2022)
Association between Type of Fluid Received Prior to Enrollment, Type of Admission, and Effect of Balanced Crystalloid in Critically Ill Adults: A Secondary Exploratory Analysis of the BaSICS Clinical Trial
Authors: Fernando G. Zampieri, Flávia R. Machado, Rodrigo S. Biondi, Flávio G. R. Freitas, Viviane C. Veiga, Rodrigo C. Figueiredo, Wilson J. Lovato, Cristina P. Amêndola, Ary Serpa-Neto, Jorge L. R. Paranhos, Eraldo A. Lúcio, Lúcio C. Oliveira-Júnior, Thiago C. Lisboa, Fábio H. Lacerda, Israel S. Maia, Cintia M. C. Grion, Murillo S. C. Assunção, Airton L. O. Manoel, Thiago D. Corrêa, Marco Antonio V. A. Guedes, Luciano C. P. Azevedo, Tamiris A. Miranda, Lucas P. Damiani, Nilton Brandão da Silva, Alexandre B. Cavalcanti
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: The effects of balanced crystalloid versus saline on clinical outcomes for ICU patients may be modified by the type of fluid that patients received for initial resuscitation and by the type of admission. Objectives: To assess whether the results of a randomized controlled trial could be affected by fluid use before enrollment and admission type. Methods: Secondary post hoc analysis of the BaSICS (Balanced Solution in Intensive Care Study) trial, which compared a balanced solution (Plasma-Lyte 148) with 0.9% saline in the ICU. Patients were categorized according to fluid use in the 24 hours before enrollment in four groups (balanced solutions only, 0.9% saline only, a mix of both, and no fluid before enrollment) and according to admission type (planned, unplanned with sepsis, and unplanned without sepsis). The association between 90-day mortality and the randomization group was assessed using a hierarchical logistic Bayesian model. Measurements and Main Results: A total of 10,520 patients were included. There was a low probability that the balanced solution was associated with improved 90-day mortality in the whole trial population (odds ratio [OR], 0.95; 89% credible interval [CrI], 0.66-10.51; probability of benefit, 0.58); however, probability of benefit was high for patients who received only balanced solutions before enrollment (regardless of admission type, OR, 0.78; 89% CrI, 0.56-1.03; probability of benefit, 0.92), mostly because of a benefit in unplanned admissions due to sepsis (OR, 0.70; 89% CrI, 0.50-0.97; probability of benefit, 0.96) and planned admissions (OR, 0.79; 89% CrI, 0.65-0.97; probability of benefit, 0.97). Conclusions: There is a high probability that balanced solution use in the ICU reduces 90-day mortality in patients who exclusively received balanced fluids before trial enrollment. Clinical trial registered with www.clinicaltrials.gov (NCT02875873).
RACIAL DISPARITIES IN PULMONARY EMBOLISM IN THE UNITED STATES FROM 1999-2019
Authors: Scott E. Janus, Ahmad Tarek Chami, Haytham Mously, Mohamad Karnib, Anshul Badhwar, Jamal Hajjari, Sadeer G. Al-Kindi
Journal: Journal of the American College of Cardiology (2022)
IDIOPATHIC ACUTE SEVERE MITRAL REGURGITATION SECONDARY TO SPONTANEOUS RUPTURE OF CHORDAE TENDINAE IN A PATIENT WITH DOWNS SYNDROME
Authors: Rida Shahid, Saneeha Shahid, Razleen Brar, Hani K. Najm, John Costello, Munir Ahmad, Rukmini R. Komarlu
Journal: Journal of the American College of Cardiology (2022)
CLINICAL CORRELATES OF ISCHEMIC AND BLEEDING RISK IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION TREATED WITH EXTENDED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR 60 MG: INSIGHTS FROM ALETHEIA, A MULTI-COUNTRY OBSERVATIONAL STUDY
Authors: Marc P. Bonaca, Eva Lesén, Evangelos Giannitsis, Tomas Jernberg, Aldo Pietro Maggioni, Albert Ariza-Solé, Jurrien M. Ten Berg, Narinder Bhalla, Robert F. Storey
Journal: Journal of the American College of Cardiology (2022)
ACUTE MANAGEMENT OF MYOCARDITIS DUE TO MULTI-SYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 INFECTION
Authors: Wojciech Rzechorzek, Dhand Abhay, Kai Masashi, Wu Hao, Lento Patrick, Lanier Gregg, Alan L. Gass, Ohira Suguru, Avi Levine
Journal: Journal of the American College of Cardiology (2022)
Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV
Authors: Zhong Fang, Yi Zhang, Zhaoqin Zhu, Cong Wang, Yao Hu, Xiuhua Peng, Dandan Zhang, Jun Zhao, Bisheng Shi, Zhongliang Shen, Min Wu, Chunhua Xu, Jieliang Chen, Xiaohui Zhou, Youhua Xie, Hui Yu, Xiaonan Zhang, Jianhua Li, Yunwen Hu, Maya Kozlowski, Antonio Bertoletti, Zhenghong Yuan
Journal: The Journal of Experimental Medicine (2022)

Hepatitis B virus exposure in children usually develops into chronic hepatitis B (CHB). Although hepatitis B surface antigen (HBsAg)-specific CD8+ T cells contribute to resolve HBV infection, they are preferentially undetected in CHB patients. Moreover, the mechanism for this rarely detected HBsAg-specific CD8+ T cells remains unexplored. We herein found that the frequency of HBsAg-specific CD8+ T cells was inversely correlated with expansion of monocytic myeloid-derived suppressor cells (mMDSCs) in young rather than in adult CHB patients, and CCR9 was upregulated by HBsAg on mMDSCs via activation of ERK1/2 and IL-6. Sequentially, the interaction between CCL25 and CCR9 mediated thymic homing of mMDSCs, which caused the cross-presentation, transferring of peripheral HBsAg into the thymic medulla, and then promoted death of HBsAg-specific CD8+ thymocytes. In mice, adoptive transfer of mMDSCs selectively obliterated HBsAg-specific CD8+ T cells and facilitated persistence of HBV in a CCR9-dependent manner. Taken together, our results uncovered a novel mechanism for establishing specific CD8+ tolerance to HBsAg in chronic HBV infection.
Association of Glyburide and Subcutaneous Insulin With Perinatal Complications Among Women With Gestational Diabetes
Authors: Monique M. Hedderson, Sylvia E. Badon, Noel Pimentel, Fei Xu, Anne Regenstein, Assiamira Ferrara, Romain Neugebauer
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Nearly 30% of individuals with gestational diabetes (GDM) do not achieve glycemic control with lifestyle modification alone and require medication treatment. Oral agents, such as glyburide, have several advantages over insulin for the treatment of GDM, including greater patient acceptance; however, the effectiveness of glyburide for the treatment of GDM remains controversial. <h3>Objective</h3> To compare the perinatal and neonatal outcomes associated with glyburide vs insulin using causal inference methods in a clinical setting with information on glycemic control. <h3>Design, Setting, and Participants</h3> The population-based cohort study included patients with GDM who required medication treatment from 2007 to 2017 in Kaiser Permanente Northern California. Machine learning and rigorous casual inference methods with time-varying exposures were used to evaluate associations of exposure to glyburide vs insulin with perinatal outcomes. Data analysis was conducted from March 2017 to July 2019. <h3>Exposures</h3> Time-varying exposure to glyburide vs insulin during pregnancy. <h3>Main Outcomes and Measures</h3> Outcomes evaluated separately included neonatal hypoglycemia, jaundice, shoulder dystocia, respiratory distress syndrome (RDS), neonatal intensive care unit (NICU) admission, size-for–gestational age, and cesarean delivery. Inverse probability weighting (IPW) estimation was used to separately compare perinatal outcomes between those initiating glyburide and insulin. This approach was combined with Super Learning for propensity score estimation to account for both baseline and time-dependent confounding in both per-protocol (primary) and intention-to-treat (secondary) analyses to evaluate sustained exposure to the same therapy. <h3>Results</h3> From 2007 to 2017, 11 321 patients with GDM (mean [SD] age, 32.9 [4.9] years) initiated glyburide or insulin during pregnancy. In multivariate models, the risk of neonatal respiratory distress was 2.03 (95% CI, 0.13-3.92) per 100 births lower and the risk of NICU admission was 3.32 (95% CI, 0.20-6.45) per 100 births lower after continuous exposure to glyburide compared with insulin. There were no statistically significant differences in glyburide vs insulin initiation in risk for neonatal hypoglycemia (0.85 [95% CI, −1.17 to 2.86] per 100 births), jaundice (0.02 [95% CI, −1.46 to 1.51] per 100 births), shoulder dystocia (−1.05 [95% CI, −2.71 to 0.62] per 100 births), or large-for–gestational age categories (−2.75 [95% CI, −6.31 to 0.80] per 100 births). <h3>Conclusions and Relevance</h3> Using data from a clinical setting and contemporary causal inference methods, our findings do not provide evidence of a difference in the outcomes examined between patients with GDM initiating glyburide compared with those initiating insulin.
EFFECT OF SGLT2 INHIBITORS ON LEFT VENTRICULAR REMODELING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Muhammad Shariq Usman, Tariq Jamal Siddiqi, Andrew Coats, Giuseppe Rosano, Gerasimos Filippatos, Stefan D. Anker, Javed Butler
Journal: Journal of the American College of Cardiology (2022)
Radioiodine for Low-Risk Thyroid Cancer — the Swinging Pendulum
Authors: David S. Cooper
Journal: New England Journal of Medicine (2022)

Differentiated thyroid cancer, the most common endocrine cancer, has three histologic subtypes: papillary, follicular, and Hürthle-cell cancers, with papillary thyroid cancers accounting for at least 80% of the total. The vast majority of patients with differentiated thyroid cancer have clinical stage I or stage II disease, with rates of death from this disease that approach zero.1 Since disease recurrence is a far more common problem than death, a staging system developed by the American Thyroid Association estimates recurrence risk on the basis of a number of pathological features, including tumor multifocality, size, and capsular invasion or angioinvasion; the degree of . . .
BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic
Authors: Sydney Beache, Aimee James, Graham Colditz, Courtney Harriss
Journal: Journal of the National Comprehensive Cancer Network (2022)

"BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic" published on 31 Mar 2022 by National Comprehensive Cancer Network.